Triple-negative breast cancer: Novel therapies and new directions

Abstract Triple-negative breast cancer (TNBC) accounts for approximately 15% of breast cancer diagnoses, and exhibits substantial overlap with basal-type and BRCA1-positive breast cancer. In recent years, a greater understanding of the biology of this disease has led to the development of numerous a...

Full description

Saved in:
Bibliographic Details
Published in:Maturitas 2009-08, Vol.63 (4), p.269-274
Main Authors: Pal, Sumanta Kumar, Mortimer, Joanne
Format: Article
Language:English
Subjects:
Basal
Biological and medical sciences
BRCA1
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
BSI-201
Female
Gynecology. Andrology. Obstetrics
Humans
Internal Medicine
Mammary gland diseases
Medical sciences
Neoadjuvant
Obstetrics and Gynecology
Olaparib
PARP
Puberal and climacteric disorders (male and female)
Receptor, ErbB-2 - biosynthesis
Receptors, Estrogen - biosynthesis
Receptors, Progesterone - biosynthesis
TNBC
Triple-negative
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Triple-negative breast cancer (TNBC) accounts for approximately 15% of breast cancer diagnoses, and exhibits substantial overlap with basal-type and BRCA1-positive breast cancer. In recent years, a greater understanding of the biology of this disease has led to the development of numerous and varied therapeutic approaches. Neoadjuvant trials using conventional cytotoxic agents such as cisplatin have demonstrated TNBC to be a relatively chemo-sensitive disease. In the current review, focus is directed towards novel targeted strategies for TNBC. Recent trials have shown the poly(ADP-ribosyl)ation polymerase (PARP) inhibitors BSI-201 and olaparib to be highly effective in TNBC and BRCA1/2-positive disease, respectively. Efforts to assess the role of antiangiogenic agents such as bevacizumab and sunitinib in TNBC are ongoing. Finally, preclinical studies provide a signal of potential activity with use of heat shock protein 90 (Hsp90) and Src inhibitors in this breast cancer subtype.
ISSN:0378-5122
1873-4111
DOI:10.1016/j.maturitas.2009.06.010